Compare MasTec Inc (MTZ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Pfizer Inc — how do they compare? MasTec Inc trades at $218.15 (market cap $17.94B), while Pfizer Inc trades at $27.77 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 8.9× MasTec Inc's market cap, and Pfizer Inc pays a 6.14% dividend while MasTec Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasTec Inc for 23 Days and Pfizer Inc for 158 Days on average.
| MTZ | PFE | |
|---|---|---|
Market Cap | $17.94B | $159.59B |
Volume | 1,292,386 | 30,937,010 |
Sector | Industrials | Health |
52-Week High | $437.51 | $29.02 |
52-Week Low | $190.08 | $23.67 |
Typical Hold Time | 23 Days | 158 Days |
Enterprise Value | $20.86B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $223.37, down 2.16% today, with technical indicators showing a neutral bias amid mixed moving average signals. The company reported strong Q1 2026 earnings beat but missed Q2 expectations, while maintaining robust revenue growth projections for 2026. Analyst sentiment remains overwhelmingly positive with 88.9% buy ratings and a $408.58 consensus price target representing significant upside potential from current levels.
MTZ's infrastructure expertise positions it well for AI-driven data center and utility investment cycles, though premium valuation metrics and recent cash flow volatility present near-term risks. The stock's investment case hinges on execution of record backlog and margin expansion amid competitive infrastructure markets.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
